EPS Value
The EPS Group contributes to improved health and
fulfillment for everyone through the creation of valuable solutions.
As our businesses and roles expand each year to meet the needs of the times, we have responded to changes in the world by continuing our business and adeptly making changes.
There are no limits to our potential to support the healthcare industry with our exceptional expertise.
We will continue to promote organizational renewal and sustainable growth in order to create a sustainable society with everyone.
Health & medicine
Our main field is the development of new drugs and medical devices, the search for treatments, and “support” for the discovery and development of supplements and foods that benefit the body. We will continue to provide new solutions with various partners in the three business segments of CRO, SMO, and CSO.
Value creation and social implementation
As lifestyles and society change, values regarding health are also changing. We are interested in everything related to health, including AI-based treatment, preventive medicine, and the ecosystem for new drug candidates. Adding new value to health and medicine to enrich the future and society. That is what we continue to work toward.
Improving quality of life
The real value we seek goes beyond health. We endeavor to solve various problems such as the environment, the community, gender, and equality to create better lives for every stakeholder. Seeking to provide healthcare and create a sustainable society for the future.
About Us
The EPS Group began in 1991 when Hao Yan, a government-sponsored student from China studying medical statistics, founded a company that created software to efficiently process medical information.
What started with just three people has steadily expanded from CRO, SMO, and CSO businesses, and it has now grown into a corporate group that provides a wide variety of support to the healthcare industry, including drug development.
In addition, we are accelerating our globalization by beginning to provide services to support drug discovery based on drug candidates in Japan and China.
IR Information Archive
You can view archives of past IR information.